Chemotherapy

- 1 Azithromycin resistance in Shigella spp. in Southeast Asia
- 2
- 3 Thomas C Darton^{1,2}, Ha Thanh Tuyen¹, Hao Chung The¹, Paul N Newton^{3,4},
- 4 David AB Dance ^{3,4,5}, Rattanaphone Phetsouvanh ³, Viengmon Davong ³,
- 5 James I Campbell¹, Nguyen Van Minh Hoang¹, Guy E Thwaites^{1,4}, Christopher M Parry^{6,7},
- 6 Duy Pham Thanh¹, and Stephen Baker^{1,4,8*}
- 7
- 8 ¹ The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University
- 9 Clinical Research Unit, Ho Chi Minh City, Vietnam
- 10 ² Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield Medical
- 11 School, Sheffield, United Kingdom
- 12 ³Lao-Oxford-Mahosot Hospital-Wellcome Trust Research Unit, Vientiane, Laos
- 13 ⁴ Centre for Tropical Medicine, Nuffield Department of Clinical Medicine, Oxford University, Oxford,
- 14 United Kingdom
- 15 ⁵ Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine,
- 16 London, United Kingdom
- 17 ⁶ Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, United Kingdom
- 18 ⁷ School of Tropical Medicine and Global Health, Nagasaki University, Japan
- 19 ⁸ The Department of Medicine, The University of Cambridge, Cambridge, United Kingdom
- 20 * Corresponding author: Professor Stephen Baker, the Hospital for Tropical Diseases, 764 Vo Van
- 21 Kiet, Quan 5, Ho Chi Minh City, Vietnam. Tel: +84 89241761 Fax: +84 89238904 sbaker@oucru.org
- 22
- 23 Running title: Shigella susceptibility to azithromycin
- 24

25 Abstract

26	Infection by Shigella spp. is a common cause of dysentery in Southeast Asia. Antimicrobials
27	are thought to be beneficial for treatment, however antimicrobial resistance in Shigella spp. is
28	becoming widespread. We aimed to assess the frequency and mechanisms associated with
29	decreased susceptibility to azithromycin in Southeast Asian Shigella isolates and use these
30	data to assess appropriate susceptibility breakpoints. Shigella isolated in Vietnam and Laos
31	were screened for susceptibility against azithromycin $(15\mu g)$ by disc diffusion and minimum
32	inhibitory concentration (MIC). Phenotypic resistance was confirmed by PCR amplification
33	of macrolide resistance loci. We compared the genetic relationships and plasmid contents of
34	azithromycin resistant S. sonnei using whole genome sequences. From 475 available Shigella
35	spp. isolated in Vietnam and Laos between 1994 and 2012, 6/181 S. flexneri (3.3%,
36	MIC≥16g/L) and 16/294 S. sonnei (5.4%, MIC≥32g/L) were phenotypically resistant to
37	azithromycin. PCR amplification confirmed a resistance mechanism in 22/475 (4.6%) isolates
38	(19 mphA and 3 ermB). Susceptibility data demonstrated the acceptability of S. flexneri
39	(MIC≥16g/L, zone≤15mm) and S. sonnei (MIC≥32g/L, zone≤11mm) breakpoints with <3%
40	discrepancy. Phylogenetic analysis demonstrated that decreased susceptibility has arisen
41	sporadically in Vietnamese S. sonnei on at least seven occasions between 2000 and 2009, but
42	failed to become established. While the proposed susceptibility breakpoints may allow better
43	recognition of resistant isolates, additional studies are required to assess the impact on clinical
44	outcome. The potential emergence of azithromycin resistance highlights the need for
45	alternative management options for Shigella infections in endemic countries.

46 Introduction

47	Organisms of the bacterial genus Shigella are a common cause of moderate to severe diarrhea
48	and dysentery in children attending day-care facilities, those living in resource-limited
49	settings, and travellers to such areas (1-5). In many low to middle-income countries (LMICs),
50	such as Vietnam, endemic shigellosis is now predominantly caused by Shigella sonnei.
51	Sustained antimicrobial pressure in LMICs has led to the emergence of resistance to the
52	antimicrobials used for treating shigellosis (6,7). In Southeast Asia, antimicrobial resistance
53	(AMR) in the Shigellae is largely being driven by the expansion of a specific S. sonnei
54	lineage, which is known as Global III (8).
55	
56	AMR within the genus Shigella is a problem for clinical management (9,10). The treatment of
57	Shigella infections with antimicrobials is recommended by most clinical guidelines,
58	predominantly to reduce the risk of onward transmission and disease complications. The
59	WHO currently recommends ciprofloxacin as first-line treatment, with pivmecillinam,
60	ceftriaxone, and azithromycin as alternative options. However, Shigella spp. are adept at
61	acquiring AMR genes and plasmids, and reports of multi-drug resistant (MDR) lineages or
62	isolates with reduced susceptibility to fluoroquinolones and third-generation cephalosporins
63	are increasing globally (11,12)
64	
65	Some recent recommendations have advocated the oral azalide antimicrobial azithromycin as
66	an alternative treatment for shigellosis, particularly infections caused by MDR organisms or
67	when fluoroquinolones are inappropriate (9,13). Clinical evidence for the efficacy of
68	azithromycin in treating shigellosis is limited (14,15), and there are presently no suitable
69	clinically derived susceptibility breakpoints to facilitate the laboratory identification of
70	Shigella spp. exhibiting azithromycin non-susceptibility. Recently updated CLSI guidelines
71	suggest epidemiological cut-off values (ECVs) of Minimum Inhibitory Concentrations (MIC)
72	≥16mg/L and MIC≥32mg/L to categories non-wild type S. flexneri and S. sonnei, respectively
73	(16). Data supporting these guidelines are limited, principally originating from reports of an

74 international outbreak of S. flexneri serotype 3a among men who have sex with men (MSM) 75 (17-19). Here, we aimed to assess the frequency and mechanisms of *Shigella* spp. isolates 76 with decreased susceptibility against azithromycin in Southeast Asia, a setting where 77 fluoroquinolone and third-generation cephalosporin resistance has become common. 78 Additionally, using a large dataset from Vietnam and Laos spanning 18 years, we aimed to 79 calculate suitable breakpoints for assessing Shigella susceptibility against azithromycin. 80 81 Materials and methods 82 Ethics statement 83 Bacterial isolates and data for this investigation originated from clinical studies approved by 84 the scientific and ethical committees of the Hospital for Tropical Diseases in HCMC, all other 85 participating hospitals, and the Oxford Tropical Research Ethics Committee (OXTREC) in 86 the United Kingdom. The study also included the characterization of bacterial isolates 87 submitted for routine diagnostic purposes. Study participants or parents of young participants 88 were required to provide written informed consent for the collection of samples and 89 subsequent analyses, except when samples were collected as part of routine care. 90 91 Study sites 92 The majority of fecal specimens from which *Shigella* spp. were isolated were collected in a 93 series of pediatric studies performed in Vietnam between 1994 and 2012, as previously 94 described (6). Briefly, children presenting with either diarrhea or dysentery were recruited 95 into observational studies (6, 20, 21), or treatment trials (22, 23) performed at the Hospital for 96 Tropical Diseases (HTD), Children's Hospital 1, or Children's Hospital 2 in Ho Chi Minh 97 City, Vietnam. Additional microbiology isolates collected for routine diagnostic purposes 98 were also included from Huế Central Hospital in Huế and Khanh Hoa General Hospital in 99 Nha Trang, Vietnam, and Mahosot Hospital in Vientiane, Laos. 100

4

AAC

Antimicrobial Agents and Chemotherapy

101 Microbiology methods

102	Fecal samples were collected and processed as previously described using standard
103	microbiological methods (6, 24). Briefly, non-lactose fermenting colonies grown on
104	MacConkey and/or Xylose Lysine Desoxycholate (XLD) agar (Oxoid), were identified
105	biochemically (API20E; biomerieux, Vietnam) and by slide agglutination with polyvalent
106	somatic (O) and monovalent serotype-specific grouping antisera (Denka Seiken, Japan in
107	Vietnam & Pro-Lab Diagnostics, UK in Laos). Azithromycin susceptibility testing against
108	was performed at a single laboratory in Vietnam using Kirby-Bauer disc diffusion method
109	(15µg disc) and by MIC antimicrobial gradient diffusion (Etest, AB Biodisk, Sweden on both
110	on Mueller-Hinton agar (Oxoid).
111	
112	Molecular methods
113	Genomic DNA was extracted from S. flexneri and S. sonnei isolates using the Wizard
114	Genomic DNA Extraction Kit (Promega) following the manufacturers' recommendations,
115	with the quality and quantity assessed using the Quant-IT Kit (Invitrogen) prior to
116	sequencing. PCR amplification for the detection of macrolide resistance genes (mphA/B,
117	ermA/B/D, ereA/B, and mefA/B) was performed as previously described (25).
118	
119	In addition, we performed phylogenetic analysis of 247 existing S. sonnei genomes (global
120	lineage III) and an additional 68 contemporary genomes of isolates collected during the same
121	period (1995-2011) (6) (accession numbers available in Table S1). Briefly, raw Illumina reads
122	were mapped against an S. sonnei reference genome (strain Ss046 chromosome, accession
123	number NC_007382 and pINV B plasmid, accession number NC_00735) using BWA and
124	SNPs were called using SAMtools (26, 27). Phylogenetic reconstruction was performed using
125	multiple alignment of SNPs by maximum-likelihood based phylogenetic inference (RAxML,
126	version 8.2.8) (28) with a GTR+GAMMA substitution model. Bootstrap support for the
127	maximum-likelihood phylogeny was accessed by 1,000 pseudo-replicates. Phylogenetic tree

Antimicrobial Agents and

Chemotherapy

128

129

130

131

132

133 isolates carrying ermB (EG430), mphA (DE891) and E. coli J53 (sodium azide resistant) (30). 134 E. coli transconjugants were selected on media containing sodium azide (100mg/L) and 135 azithromycin (24mg/L). ErmB/mphA-containing plasmids were extracted using plasmid Midi 136 kit (Qiagen) and sequenced using the MiSeq Illumina platform with 2x250bp pair-end reads. 137 De novo assembly was performed using SPADES v3.6.2 and annotated using Prokka (v1.11) 138 (31,32). ABACAS was used to map all the assembled contigs against a concatenated 139 reference sequence containing S. sonnei Ss046 chromosome (NC_007382), virulence plasmid 140 pSs046 (NC_007385.1) and three small plasmids commonly found in S. sonnei belonging to 141 Global lineage III: spA (NC_009345.1) spB (NC_009346.1), spC (NC_009347.1) (33). The 142 unmapped assembled sequences were presumed to contain *ermB/mphA*-encoding plasmids 143 and Incompatibility (Inc) groups were then determined using in silico PCR by mapping the 144 primers described previously to these unmapped sequences using an in-house script at the 145 Sanger Institute (34). The presence of the ermB/mphA plasmid was confirmed by BLASTN 146 searching the plasmid sequences to the previously sequenced plasmids in Genbank and 147 comparative analysis was performed and visualized using ACT (35). 148 149 Statistical analysis 150 Statistical analysis of *Shigella* spp. isolates was limited to *S. flexneri* and *S. sonnei* only, as 151 insufficient numbers of other species were available (Table 1). For comparisons of 152 proportions of non-susceptible isolates, intermediate and resistant isolates were grouped 153 together and compared with the proportion of susceptible isolates using Fisher's exact test.

resistance genes over the study period among terminal taxa.

Plasmid isolation and sequencing

was displayed and annotated using iTOL (29), highlighting the presence/absence of macrolide

Bacterial conjugation was performed as described previously by combining representative

- 154 Comparison of MIC measurements from different time periods was performed by ANOVA
- 155 and subsequent Dunn's test with Bonferroni correction for multiple testing, with a threshold

σ		
Ē		
σ		
2		
Ξ.		>
5	ŝ	0
ണ്	3	9
2		
4	_	<u> </u>
-	4	
2	- (2
0	1	Ξ
0	- (ð
	_	1
≅	(J
E		1
-		

- 156 of p < 0.05 considered significant. To determine appropriate azithromycin breakpoints, MIC
- 157 histograms were constructed and disc zone diameter breakpoints were selected using the
- 158 modified error rate-bounding method of Metzler and De Haan, according to CLSI
- 159 recommendations (36).
- 160 Accession no(s). The sequence for plasmid pDE105 has been deposited in GenBank under
- 161 accession no. MG569891.

162 Results

- 163 Decreased susceptibility to azithromycin in Shigella spp. in Southeast Asia
- 164 Data from a total of 517 Shigella (198 S. flexneri, 308 S. sonnei, and 11 others) isolated
- 165 between 1994 and 2012 in Vietnam (6 studies, 472 isolates) and Laos (45 isolates) (Table 1)
- 166 were available for antimicrobial susceptibility analysis. In this collection of organisms,
- 167 180/198 (91%) S. flexneri were defined as being MDR (resistant to ≥3 classes of
- 168 antimicrobials), 3/196 (2%) were resistant to ceftriaxone, and 78/196 (40%) were resistant to
- 169 nalidixic acid. In contrast, significantly fewer S. sonnei isolates were MDR (181/308, 59%;
- 170 p < 0.0001), while a greater proportion exhibited resistance to ceftriaxone (92/307, 30%;
- 171 *p*<0.0001), and nalidixic acid (174/307, 69%; *p*=0.0003) (20).
- 172
- 173 From the 517 Shigella isolates collected over the defied period, 479 were recovered and
- 174 available for azithromycin susceptibility testing; 181/479 (37.8%) S. flexneri, 294/479
- 175 (61.4%) S. sonnei, and 4/479 (0.8%) isolates belonging to other Shigella species (not
- 176 considered further). The distributions of the azithromycin MICs against azithromycin of the
- 177 475 Shigella isolates collected over the sampling period are shown in Figure 1. The combined
- 178 MIC₅₀ for azithromycin was 4mg/L (MIC₉₀, 8mg/L); the S. sonnei isolates exhibited a higher
- 179 range of MIC values (IQR, 4 to 8 mg/L) in comparison with the S. flexneri isolates (IQR, 2 to
- 180 4mg/L). The proportion of S. flexneri isolates with an MIC \geq 16mg/L was 6/181 (3.3%,
- 181 95%CI, 1.4 to 7.4), whereas the proportion of S. sonnei isolates with an MIC \geq 32mg/L was
- 182 16/294 (5.4%, 3.2 to 8.9; p>0.05).
- 183

intimicrobial Agents and

184

185

186 mphA/B, ereA/B, and msrA and mefA, which encode antimicrobial efflux mechanisms. 187 Nucleic acid extractions from 19/475 (4.0%) isolates generated an amplicon for mphA; 14 S. 188 sonnei and 5 S. flexneri (Table 2). The majority of these organisms had azithromycin MICs of 189 \geq 32mg/L with a corresponding zone of inhibition of \leq 14mm; three *S. flexneri* isolates had 190 azithromycin MICs of 16mg/L and zone sizes of 11 and 12mm (2 isolates) to a 15µg 191 azithromycin disc. A further three organisms produced ermB amplicons (3/475, 0.6%). The 192 only ermB amplification positive S. flexneri isolate had a lower MIC (16mg/L) and larger 193 inhibition zone size (12mm) in comparison to the two S. sonnei isolates (MIC 32mg/L, zone 194 size 9mm). These data suggest that S. sonnei and S. flexneri exhibit different distribution of 195 MICs when harboring the mphA and/or ermB genes. 196 197 Determining disc susceptibility breakpoints for azithromycin 198 The CLSI recently provided ECV for determining azithromycin resistance in S. flexneri (disc 199 diffusion and MIC) and S. sonnei (MIC only) (16). While ECVs are not generally 200 recommended for determining clinical susceptibility breakpoints, we used these same criteria 201 in our dataset, given that clinical data on azithromycin usage was not available. We aimed to 202 determine whether the CLSI cut-off values could be used to determine suitable disc diffusion 203 breakpoints for S. sonnei. Azithromycin disc inhibition zone sizes were available for 181 S. 204 flexneri and 294 S. sonnei isolates. A regression analysis for determining the suitability of 205 MIC data to extrapolate disc diffusion breakpoints demonstrated a significant correlation 206 between MIC and disc diffusion zone size for S. flexneri (rho, -0.845; p<0.0001; Spearman) 207 and to a lesser extent for S. sonnei (rho, -0.649; p<0.001). 208 209 For S. flexneri, a breakpoint zone size of ≤ 15 mm exhibited good discrimination against a 210 15µg azithromycin disc to identify non-susceptible isolates. Using an error rate-bounding

Genes conferring decreased susceptibility against azithromycin

Isolates were screened by PCR amplification for the macrolide resistance genes *ermA/B/C*,

211 method, a 3% major error rate was found, and with a \leq 15mm breakpoint there were no very

Antimicrobial Agents and Chemotherapy

AAC

major or minor errors when compared an MIC of $\leq 8mg/L$ (Table 3, Figure 2), thereby
fulfilling CLSI recommendations (36). In contrast, while the ECV MIC threshold of \geq 32mg/L
appeared to define non-susceptible S. sonnei, no clear demarcation in disc diffusion zone size
measurements was observed (Figure 2). The largest azithromycin zone of inhibition in the S.
sonnei isolates with a known azithromycin resistance mechanism was 9mm. We aimed to
identify the largest zone size concordant with a permissible CLSI error rate. We determined
that a cut-off of ≤ 11 mm resulted in an acceptable discrepancy rate (Table 3), whereas ≤ 12 mm
resulted in a 6.5% major error rate.
Plasmid structures and phylogenetic context of azithromycin resistant Shigella sonnei
As observed previously, phylogenetic analyses confirmed that all genome-sequenced
Vietnamese S. sonnei isolates belonged to the same clade of the Global III lineage (37).
Investigation of the accessory genome confirmed that resistance to azithromycin within these
S. sonnei isolates was mediated by either ermB or mphA in 16 of the sequenced isolates
(Figure 3). Two of the 16 azithromycin-resistant isolates carried an <i>ermB</i> gene; the remaining
14 carried an mphA gene. Notably, unlike the phenotypes of reduced susceptibility to
fluoroquinolones and resistance against third generation cephalosporins (38), these
azithromycin resistance genes were not restricted to individual sub-lineages or clonal
expansions. Indeed, we estimated that between 2001 and 2008 ermB was acquired
independently on at least two separate occasions, whilst mphA was acquired on at least five
separate occasions, forming a small sub-clade of azithromycin-resistant organisms on two
instances (Figure 3). However, these azithromycin resistance genes were transient and
appeared not to be maintained within the population.
Additional in silico analysis of the azithromycin resistance plasmids demonstrated that ermB
was associated with two differing plasmid structures; S. sonnei 20094 harbored an IncFI
plasmid (p20094) and S. sonnei EG430 carried an IncFII plasmid (pEG430-2). The IncFI
plasmid (p20094) was assembled and found to be approximately 82kb in size, sharing 99%

()
<		C
<	⊲	ĺ

240	DNA sequence identity with pEG356 (accession: FN594520.1), which we previously
241	characterized in the Vietnamese S. sonnei isolate, EG356 (38). Similar to plasmid pEG356,
242	p20094 carried a <i>bla</i> _{CTX-M-24} downstream of an IS <i>Ecp1</i> . However, this replicon additionally
243	contained an ISCR3 insertion sequence encompassing both the <i>ermB</i> and <i>ermC</i> genes. The
244	IncFII plasmid pEG430-2 (accession LT174531.1) was 68,999bp and harbored <i>ermB</i> and
245	ermC genes downstream of an IS6 transposase and had a 33,429bp DNA transfer region
246	comprised of 37 contiguous genes (Figure 4a). Plasmid pEG430-2 shared significant DNA
247	homology to other two other previously sequenced IncFII plasmids, p183660 (KX008967;
248	coverage 86% and identity 98%) and pKSR100 (LN624486, coverage 89%, identity 98%),
249	which were respectively identified in S. sonnei and S. flexneri 3a isolates associated with
250	disease in MSM.
251	

252	Despite the erratic distribution of the mphA gene in the 2000 and 2010 S. sonnei isolates,
253	sequence analysis demonstrated that these isolates likely carried mphA on a similar IncI
254	plasmid backbone of a comparable size. A de novo assembly of S. sonnei DE105 effectively
255	produced an entire plasmid sequence of 113,548bp, designated as pDE105 (accession
256	number: MG569891) (Figure 4b). Plasmid pDE105 was analogous in size and structure to a
257	previously described IncI plasmid pHV292 from an E. coli identified in the poultry
258	production system in Switzerland (accession: KM377239.1). The mphA gene was located
259	downstream of an IS3/IS911 transposase (orfA-orfB) and several additional AMR genes
260	associated with a <i>tnpA</i> transposon and conferring resistance against sulphanomides (<i>folP</i>),
261	streptomycin (strepAB), ß-lactams (bla-TEM-1), and tetracycline (tetA-tetR). Plasmid
262	pDE105 also contained a type IV secretion system with tral/tral genes responsible for
263	conjugal transfer and an operon for pilus biosynthesis (pill, pilQ, pilM, pilN, pilO, and pilP).
264	
265	We lastly performed plasmid isolation and sequencing on an additional S. sonnei isolate
266	(DE891), which was distantly related to DE105. A de novo plasmid assembly produced seven

267 contiguous sequences of 115kb spanning 99.6% of pDE105 and had 99% DNA sequence

Antimicrobial Agents and

Chemotherapy

295

268

269 Vietnamese S. sonnei. Mapping the remaining mphA plasmid sequences against pDE105, we 270 found that they all shared a common genetic synteny (~90kb), which contained the same 271 resistance gene cassettes. 272 273 Discussion 274 Azithromycin is a commonly though to be last resort drug for dysentery, but an increasing 275 number of reports of decreased susceptibility against azithromycin in Shigella isolates is 276 concerning. This problem has been observed in disparate populations including among MSM 277 in affluent areas and children with dysentery in LMICs. Antimicrobial options for treating 278 MDR and/or ciprofloxacin-resistant Shigella spp. are limited, especially for children or when 279 an oral antimicrobial is required. In this large set of clinical Shigella spp. isolates collected 280 over 18 years in Vietnam and Laos, both countries in which Shigella-associated dysentery in 281 endemic, we found a low proportion (~5%) of Shigella isolates with decreased susceptibility 282 to azithromycin. This low rate of non-susceptibility may be associated with the initial low 283 rates of nalidixic acid and ciprofloxacin resistance and thus limited azithromycin usage. To 284 our knowledge, this is the largest collection of Shigella spp. exhibiting decreased 285 susceptibility against azithromycin reported from this region. Plasmid-mediated acquisition of 286 mphA and ermB were identified as the principal mechanisms for azithromycin resistance. 287 288 As human-restricted pathogens, Shigella spp. likely acquire resistance from the colonizing 289 microbiota by plasmid transfer. This phenomenon has previously been demonstrated with E. 290 coli donating mphA to S. sonnei (25). All of the identified mphA-associated plasmids have 291 previously been described in E. coli, supporting their role as a reservoir from which AMR 292 Shigella spp. may emerge. We demonstrate that the mechanism of azithromycin resistance to 293 Shigella spp. arose sporadically during this period through at least seven plasmid acquisition 294 events at different time points (from 2000 to 2009). Shigella spp. harboring azithromycin-

identity. These data confirmed a common IncI plasmid backbone within the mphA positive

resistance plasmids appear not to have been maintained within the population, which may be

AAC

Antimicrobial Agents and Chemotherapy

296	associated with a lack of antimicrobial selection pressure, heterogeneity in the populations
297	sampled, or simply due to instability of the described resistance plasmids. There was only one
298	example in the S. sonnei population in which an mphA-harboring plasmid sub-clade was
299	maintained for at least two years (2000-2001).
300	
301	Given the limited antimicrobial treatment options available for Shigella-associated dysentery
302	and the now widespread use of azithromycin, it is critical that laboratories can identify
303	clinical isolates non-susceptible to azithromycin. We assessed the suitability of recently
304	published ECVs for use as clinical susceptibility breakpoints. The MIC and disc zone sizes
305	for S. flexneri in this study were consistent with the ECV guidance proposed by CLSI for
306	MIC and disc diffusion measurements to identify non-wild type S. flexneri isolates, based on
307	the detection of a resistance mechanism (16). In contrast, the distribution of MICs for
308	azithromycin in S. sonnei were not concordant with the CLSI ECV guidance with a skew to
309	the right. Our data support a higher ECV and susceptibility breakpoint for S. sonnei of
310	\geq 32mg/L, and that a tentative zone size of \leq 11mm around a 15µg azithromycin disc can
311	identify non-wild type isolates. These thresholds are supported by confirmatory PCR
312	amplifications and genome sequencing which corroborated the presence of azithromycin
313	resistance gene in these 22 non-wild type isolates, and demonstrated an acceptably small
314	proportion of discrepancies according to CLSI criteria (36).
315	
316	Limitations to our interpretations include the retrospective nature of the data analysis from the
317	associated collection of organisms and a lack of clinical outcome data. The clinical impact of
318	reductions in azithromycin susceptibility is uncertain, as azithromycin achieves a high
319	concentration in intracellular compartments, such as within macrophages and colonic
320	epithelial cells. The pathogenesis of Shigella spp. requires colonic epithelial cells for
321	invasion, intracellular survival, and replication (8). Consequently a positive clinical outcome
322	may be achieved even in the context of reduced in vitro susceptibility. Additionally, broth or
323	agar dilution methods are the recognized standard method for MIC determination, and a
	12
	12

previous study has demonstrated potential issues with measuring disc diffusion and Etests to
determine azithromycin susceptibility (39). In a small study, Jain et al. demonstrated a double
zone phenomenon for both methods and reported that broth dilution MICs corresponded with
values intermediate to inner and outer zones. While zone size interpretation may be a
limitation, we additionally performed genotypic screening for associated resistance genes on
all isolates, confirming our phenotypic testing results. Despite these limitations, the major
strengths of our analyses include the large dataset of clinical isolates, the wide range of
azithromycin MICs and the repeat testing of all isolates at a single center, thus limiting inter-
laboratory technical and interpretation errors.
While azithromycin resistance among Shigella spp. causing dysentery and diarrhea was not
common in the 18-year period between 1994 and 2012 in the sampled locations, the
increasing proportion of MDR, fluoroquinolone and third generation cephalosporin resistant
isolates will inevitably lead to the increasing use of azithromycin. During the sampling
period, Shigella spp. with decreased susceptibility to azithromycin emerged on several
separate occasions, but failed to become established in the population. Azithromycin is being
increasingly used for the treatment of suspected and confirmed Shigella infections in LMICs,
despite limited evidence. In this study we have developed tentative susceptibility breakpoints
that we suggest should be evaluated in other locations. Correlation with proposed breakpoints
and clinical outcomes in azithromycin-treated patients is a further priority. MIC and disc
susceptibility breakpoints are urgently needed for the active global surveillance for
azithromycin resistant strains of Shigella spp. Assessment of new alternative treatments are
also required to stay ahead of this potential public health problem.
Acknowledgements
We are grateful to all of the study participants and patients who have taken part in these
studies. We also gratefully acknowledge the support of participant's parents and additional
clinical and laboratory staff for their assistance in collection and processing of samples and
12

Antimicrobial Agents and Chemotherapy

Antimicrobial Agents and Chemotherapy

Chemotherapy

352 bacterial isolates respectively. In Lao, we are very grateful to Assoc. Prof. Bounthaphany 353 Bounxouei the Director of Mahosot Hospital, the staff of Mahosot Hospital, Assoc. Prof. 354 Chanphomma Vongsamphan, the Director of Department of Health Care, Ministry of Health, 355 and Assoc. Prof. Bounkong Syhavong, Minister of Health, Lao PDR for their very kind help 356 and support.

357

358 Funding

359 This work was supported by the National Institutes for Health Research (Academic Clinical 360 Lectureship grant number 3557 to TCD); the Academy of Medical Sciences and Wellcome 361 Trust (Clinical Lecturer Starter Grant number SGCL015/1005 to TCD); the Wellcome Trust 362 (grant number 098051 to HCT, grant number 089276/2/09/2 to JIC and GT, grant number 363 106698/Z/14/Z to DABD, PNN, RP and VD); the Oak Foundation (leadership fellow grant 364 number B9R00910 to PTD); and the Wellcome Trust and Royal Society (Sir Henry Dale 365 Fellowship grant number 10008/Z/12/Z to SB). 366

367 Transparency

- 368 The authors declare no competing interests.
- 369

370 References

371	1.	Kotloff KL, Nataro JP, Blackwelder WC, Nasrin D, Farag TH, Panchalingam S, Wu
372		Y, Sow SO, Sur D, Breiman RF, Faruque ASG, Zaidi AKM, Saha D, Alonso PL,
373		Tamboura B, Sanogo D, Onwuchekwa U, Manna B, Ramamurthy T, Kanungo S,
374		Ochieng JB, Omore R, Oundo JO, Hossain A, Das SK, Ahmed S, Qureshi S, Quadri
375		F, Adegbola RA, Antonio M, Hossain MJ, Akinsola A, Mandomando I, Nhampossa
376		T, Acácio S, Biswas K, O'Reilly CE, Mintz ED, Berkeley LY, Muhsen K,
377		Sommerfelt H, Robins-Browne RM, Levine MM. 2013. Burden and aetiology of
378		diarrhoeal disease in infants and young children in developing countries (the Global

380		382:209-222.
381	2.	Platts-Mills JA, Babji S, Bodhidatta L, Gratz J, Haque R, Havt A, McCormick BJJ,
382		McGrath M, Olortegui MP, Samie A, Shakoor S, Mondal D, Lima IFN, Hariraju D,
383		Rayamajhi BB, Qureshi S, Kabir F, Yori PP, Mufamadi B, Amour C, Carreon JD,
384		Richard SA, Lang D, Bessong P, Mduma E, Ahmed T, Lima AAAM, Mason CJ,
385		Zaidi AKM, Bhutta ZA, Kosek M, Guerrant RL, Gottlieb M, Miller M, Kang G,
386		Houpt ER. 2015. Pathogen-specific burdens of community diarrhoea in developing
387		countries: a multisite birth cohort study (MAL-ED). The Lancet Global Health
388		3:e564-e575.
389	3.	Kim JS, Kim JJ, Kim SJ, Jeon SE, Seo KY, Choi JK, Kim NO, Hong S, Chung GT,
390		Yoo CK, Kim YT, Cheun HI, Bae GR, Yeo YH, Ha GJ, Choi MS, Kang SJ, Kim J.
391		2015. Outbreak of Ciprofloxacin-Resistant Shigella sonnei Associated with Travel to
392		Vietnam, Republic of Korea. Emerg Infect Dis 21:1247-50.
393	4.	Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ,
394		Adak GK, Levine MM. 1999. Global burden of Shigella infections: implications for
395		vaccine development and implementation of control strategies. Bull World Health
396		Organ 77:651-66.
397	5.	Haley CC, Ong KL, Hedberg K, Cieslak PR, Scallan E, Marcus R, Shin S, Cronquist
398		A, Gillespie J, Jones TF, Shiferaw B, Fuller C, Edge K, Zansky SM, Ryan PA,
399		Hoekstra RM, Mintz E. 2010. Risk factors for sporadic shigellosis, FoodNet 2005.
400		Foodborne Pathog Dis 7:741-7.
401	6.	Holt KE, Thieu Nga TV, Thanh DP, Vinh H, Kim DW, Vu Tra MP, Campbell JI,
402		Hoang NV, Vinh NT, Minh PV, Thuy CT, Nga TT, Thompson C, Dung TT, Nhu NT,
403		Vinh PV, Tuyet PT, Phuc HL, Lien NT, Phu BD, Ai NT, Tien NM, Dong N, Parry
404		CM, Hien TT, Farrar JJ, Parkhill J, Dougan G, Thomson NR, Baker S. 2013.
405		Tracking the establishment of local endemic populations of an emergent enteric
406		pathogen. Proc Natl Acad Sci U S A 110:17522-7.

Enteric Multicenter Study, GEMS): a prospective, case-control study. The Lancet

Antimicrobial Agents and	Chemotherapy

407	7.	Thompson CN, Duy PT, Baker S. 2015. The Rising Dominance of Shigella sonnei:
408		An Intercontinental Shift in the Etiology of Bacillary Dysentery. PLoS Negl Trop Dis
409		9:e0003708.
410	8.	The HC, Thanh DP, Holt KE, Thomson NR, Baker S. 2016. The genomic signatures
411		of Shigella evolution, adaptation and geographical spread. Nat Rev Microbiol 14:235-
412		50.
413	9.	Erdman SM. 2008. Options for Treating Resistant Shigella Species Infections in
414		Children. 13:29-43.
415	10.	Thompson CN, Thieu NT, Vinh PV, Duc AN, Wolbers M, Vinh H, Campbell JI,
416		Ngoc DT, Hoang NV, Thanh TH, The HC, Nguyen TN, Lan NP, Parry CM, Chau
417		NV, Thwaites G, Thanh DP, Baker S. 2016. Clinical implications of reduced
418		susceptibility to fluoroquinolones in paediatric Shigella sonnei and Shigella flexneri
419		infections. J Antimicrob Chemother 71:807-15.
420	11.	Nuesch-Inderbinen M, Heini N, Zurfluh K, Althaus D, Hachler H, Stephan R. 2016.
421		Shigella Antimicrobial Drug Resistance Mechanisms, 2004-2014. Emerg Infect Dis
422		22:1083-5.
423	12.	Aggarwal P, Uppal B, Ghosh R, Krishna Prakash S, Chakravarti A, Jha AK,
424		Rajeshwari K. 2016. Multi drug resistance and Extended Spectrum Beta Lactamases
425		in clinical isolates of Shigella: A study from New Delhi, India. Travel Med Infect Dis
426		14:407-13.
427	13.	American Academy of Pediatrics. 2015. Shigella infections, p 706-709. In Kimberlin
428		DW, Brady MT, Jackson MA, Long SS (ed), Red Book: 2015 Report of the
429		Committee on Infectious Diseases, 30th ed. American Academy of Pediatrics, Elk
430		Grove Village, IL.
431	14.	Khan WA, Seas C, Dhar U, Salam MA, Bennish ML. 1997. Treatment of shigellosis:
432		V. Comparison of azithromycin and ciprofloxacin. A double-blind, randomized,
433		controlled trial. Ann Intern Med 126:697-703.

AAC

434

15.

435		cefixime for treatment of shigellosis in children. Pediatr Infect Dis J 22:374-7.
436	16.	CLSI. 2016. Performance Standards for Antimicrobial Susceptibility Testing. 26th
437		ed., 26th ed ed. Clinical and Laboratory Standards Institute, Wayne, PA.
438	17.	Baker KS, Dallman TJ, Ashton PM, Day M, Hughes G, Crook PD, Gilbart VL,
439		Zittermann S, Allen VG, Howden BP, Tomita T, Valcanis M, Harris SR, Connor TR,
440		Sintchenko V, Howard P, Brown JD, Petty NK, Gouali M, Thanh DP, Keddy KH,
441		Smith AM, Talukder KA, Faruque SM, Parkhill J, Baker S, Weill F-X, Jenkins C,
442		Thomson NR. 2015. Intercontinental dissemination of azithromycin-resistant
443		shigellosis through sexual transmission: a cross-sectional study. The Lancet
444		Infectious Diseases 15:913-921.
445	18.	Heiman KE, Karlsson M, Grass J, Howie B, Kirkcaldy RD, Mahon B, Brooks JT,
446		Bowen A. 2014. Notes from the field: Shigella with decreased susceptibility to
447		azithromycin among men who have sex with men - United States, 2002-2013.
448		MMWR Morb Mortal Wkly Rep 63:132-3.
449	19.	Valcanis M, Brown JD, Hazelton B, O'Sullivan MV, Kuzevski A, Lane CR, Howden
450		BP. 2015. Outbreak of locally acquired azithromycin-resistant Shigella flexneri
451		infection in men who have sex with men. Pathology 47:87-8.
452	20.	Vinh H, Nhu NT, Nga TV, Duy PT, Campbell JI, Hoang NV, Boni MF, My PV,
453		Parry C, Nga TT, Van Minh P, Thuy CT, Diep TS, Phuong le T, Chinh MT, Loan
454		HT, Tham NT, Lanh MN, Mong BL, Anh VT, Bay PV, Chau NV, Farrar J, Baker S.
455		2009. A changing picture of shigellosis in southern Vietnam: shifting species
456		dominance, antimicrobial susceptibility and clinical presentation. BMC Infect Dis
457		9:204.
458	21.	Thompson CN, Phan VT, Le TP, Pham TN, Hoang LP, Ha V, Nguyen VM, Pham
459		VM, Nguyen TV, Cao TT, Tran TT, Nguyen TT, Dao MT, Campbell JI, Nguyen TC,
460		Tang CT, Ha MT, Farrar J, Baker S. 2013. Epidemiological features and risk factors

Basualdo W, Arbo A. 2003. Randomized comparison of azithromycin versus

AAC

Antimicrobial Agents and Chemotherapy

461		of Salmonella gastroenteritis in children resident in Ho Chi Minh City, Vietnam.
462		Epidemiol Infect 141:1604-13.
463	22.	Vinh H, Wain J, Chinh MT, Tam CT, Trang PT, Nga D, Echeverria P, Diep TS,
464		White NJ, Parry CM. 2000. Treatment of bacillary dysentery in Vietnamese children:
465		two doses of ofloxacin versus 5-days nalidixic acid. Trans R Soc Trop Med Hyg
466		94:323-6.
467	23.	Vinh H, Anh VT, Anh ND, Campbell JI, Hoang NV, Nga TV, Nhu NT, Minh PV,
468		Thuy CT, Duy PT, Phuong le T, Loan HT, Chinh MT, Thao NT, Tham NT, Mong
469		BL, Bay PV, Day JN, Dolecek C, Lan NP, Diep TS, Farrar JJ, Chau NV, Wolbers M,
470		Baker S. 2011. A multi-center randomized trial to assess the efficacy of gatifloxacin
471		versus ciprofloxacin for the treatment of shigellosis in Vietnamese children. PLoS
472		Negl Trop Dis 5:e1264.
473	24.	Standards Unit, Microbiology Services, PHE. 2015. UK Standards for Microbiology
474		Investigations, vol ID20. PHE, Colindale.
475	25.	Phuc Nguyen MC, Woerther PL, Bouvet M, Andremont A, Leclercq R, Canu A.
476		2009. Escherichia coli as reservoir for macrolide resistance genes. Emerg Infect Dis
477		15:1648-50.
478	26.	Li H. 2011. A statistical framework for SNP calling, mutation discovery, association
479		mapping and population genetical parameter estimation from sequencing data.
480		Bioinformatics 27:2987-93.
481	27.	Li H. 2013. Aligning sequence reads, clone sequences and assembly contigs with
482		BWA-MEM. arXiv:13033997v1 [q-bioGN].
483	28.	Stamatakis A. 2014. RAxML version 8: a tool for phylogenetic analysis and post-
484		analysis of large phylogenies. Bioinformatics 30:1312-1313.
485	29.	Letunic I, Bork P. 2016. Interactive tree of life (iTOL) v3: an online tool for the
486		display and annotation of phylogenetic and other trees. Nucleic Acids Res 44:W242-
487		5.

488	30.	Pham Thanh D, Thanh Tuyen H, Nguyen Thi Nguyen T, Chung The H, Wick RR,
489		Thwaites GE, Baker S, Holt KE. 2016. Inducible colistin resistance via a disrupted
490		plasmid-borne mcr-1 gene in a 2008 Vietnamese Shigella sonnei isolate. J
491		Antimicrob Chemother 71:2314-7.
492	31.	Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, Lesin VM,
493		Nikolenko SI, Pham S, Prjibelski AD, Pyshkin AV, Sirotkin AV, Vyahhi N, Tesler G,
494		Alekseyev MA, Pevzner PA. 2012. SPAdes: a new genome assembly algorithm and
495		its applications to single-cell sequencing. J Comput Biol 19:455-77.
496	32.	Seemann T. 2014. Prokka: rapid prokaryotic genome annotation. Bioinformatics
497		30:2068-9.
498	33.	Assefa S, Keane TM, Otto TD, Newbold C, Berriman M. 2009. ABACAS:
499		algorithm-based automatic contiguation of assembled sequences. Bioinformatics
500		25:1968-9.
501	34.	Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 2005.
502		Identification of plasmids by PCR-based replicon typing. J Microbiol Methods
503		63:219-28.
504	35.	Carver TJ, Rutherford KM, Berriman M, Rajandream M-A, Barrell BG, Parkhill J.
505		2005. ACT: the Artemis comparison tool. Bioinformatics 21:3422-3423.
506	36.	NCCLS. 2001. Development of in vitro susceptiblity testing criteria and quality
507		control parameters; approved guideline - Second Edition. NCCLS, 940 West Valley
508		Road, Suite 1400, Wayne, Pennsylvania 19087-1898, USA.
509	37.	Chung The H, Rabaa MA, Pham Thanh D, De Lappe N, Cormican M, Valcanis M,
510		Howden BP, Wangchuk S, Bodhidatta L, Mason CJ, Nguyen Thi Nguyen T, Vu Thuy
511		D, Thompson CN, Phu Huong Lan N, Voong Vinh P, Ha Thanh T, Turner P, Sar P,
512		Thwaites G, Thomson NR, Holt KE, Baker S. 2016. South Asia as a Reservoir for the
513		Global Spread of Ciprofloxacin-Resistant Shigella sonnei: A Cross-Sectional Study.
514		PLoS Med 13:e1002055.

515	38.	Nhu NTK, Vinh H, Nga TVT, Stabler R, Duy PT, Thi Minh Vien L, van Doorn HR,
516		Cerdeño-Tárraga A, Thomson N, Campbell J, Van Minh Hoang N, Thi Thu Nga T,
517		Minh PV, Thuy CT, Wren B, Farrar J, Baker S. 2010. The Sudden Dominance of
518		blaCTX-M Harbouring Plasmids in Shigella spp. Circulating in Southern Vietnam.
519		PLOS Neglected Tropical Diseases 4:e702.
520	39.	Jain SK, Gupta A, Glanz B, Dick J, Siberry GK. 2005. Antimicrobial-Resistant
521		Shigella sonnei. The Pediatric Infectious Disease Journal 24:494-497.
	516 517 518 519 520	516 517 518 519 520 39.

AAC

Table 1. Origin of Shigella isolates and frequency of selected resistance azithromycin markers 522

a			Shigella	species		An	timicrobial resista	nce markers n/N	(%)
Country/Study code	Period	S. flexneri	S. sonnei	Other	Total	DSA	NAL	CRO	MDR
Vietnam/MS	1994-1998	58	22	0	80	3/70 (4.3)	1/80 (1.3)	0/80 (0)	57/80 (72.5)
Vietnam/DE	2000-2002	42	62	8 ^A	112	10/93 (10.8)	32/111 (28.8)	1/111 (0.9)	80/112 (71.4)
Laos	2006-2012	35	9	1^{B}	45	0/45 (0)	14/45 (31.1)	0/45 (0)	34/45 (75.6)
Vietnam/EG	2007-2008	30	78	2^{C}	110	4/104 (3.8)	75/108 (69.4)	22/108 (20.3)	96/110 (87.3)
Vietnam/Huế	2008-2010	21	37	0	58	1/56 (1.8)	27/58 (46.6)	7/58 (12.0)	24/58 (41.4)
Vietnam/AV	2009-2010	4	58	0	62	3/61 (4.9)	58/62 (93.5)	47/62 (75.8)	52/62 (83.9)
Vietnam/KH	2009-2010	8	42	0	50	1/50 (2.0)	47/50 (94.0)	18/50 (36.0)	25/50 (50)
Total		198	308	11	517	22/479 (4.8)	254/514 (49.4)	95/514 (18.5)	368/517 (71.2)

523 524 DSA, decreased sensitivity to azithromycin (S. flexneri MIC≥16mg/L; S. sonnei MIC≥32mg/L)

525 526 NAL, nalidixic acid (zone<19mm); CRO, ceftriaxone resistant organism (zone<23mm)

MDR, multidrug resistant: intermediate or resistant to ≥ 3 classes of antimicrobials: penicillins (ampicillin), cephems (ceftriaxone), folate inhibitors

527 528 (trimethoprim), phenicols (chloramphenicol), tetracyclines (tetracycline), quinolones (specifically nalidixic acid resistance), aminoglycosides (gentamicin) Study code, as per description in Reference 6. NA, not available; ^A 1 *S. boydii*, 1 *S. dysenteriae*, 6 NA; ^B 1 *S. boydii*; ^C 2 *S. boydii*.

529

Table 2. Source, microbiological and genotypic characteristics of Shigella spp. isolates with decreased susceptibility to azithromycin

Isolate ID MS025 MS052	Organism	Year	Age	Azithromycin	susceptibility	Resistance gene	ESBL	MDF	
Isolate ID	Organishi	Tear	(years)	MIC (mg/L)	Zone (mm)	Resistance gene	ESDL	MDK	
MS025	S. flexneri 2a	1994-1998	0.75	32	11	mphA	-	+	
MS052	S. flexneri	1994-1998	0.83	16	14	mphA	-	+	
MS055	S. flexneri 6	1994-1998	0.92	512	6	mphA	-	+	
DE0088	S. sonnei	2000	4.00	512	6	mphA	-	+	
DE0105	S. sonnei	2000	1.50	512	6	mphA	-	+	
DE0108	S. sonnei	2000	1.50	512	6	mphA	-	+	
DE0185	S. sonnei	2000	0.67	512	6	mphA	-	+	
DE0199	S. sonnei	2000	2.42	512	6	mphA	-	+	
DE0490	S. sonnei	2000	1.67	512	6	mphA	-	+	
DE0579	S. sonnei	2001	4.00	512	6	mphA	-	+	
DE0885	S. sonnei	2001	3.00	512	6	mphA	-	+	
DE0891	S. sonnei	2001	1.50	128	6	mphA	-	+	
DE1336	S. sonnei	2002	1.92	512	6	mphA	-	+	
EG0094	S. sonnei	2007	2.58	256	6	mphA	-	+	
EG0352	S. sonnei	2007	2.50	256	6	mphA	-	+	
EG0419	S. flexneri 2a	2007	1.92	16	12	ermB	-	+	
EG0430	S. sonnei	2008	3.00	32	9	ermB	+	+	
Huế 49	S. flexneri	2009	4.00	128	6	mphA	-	+	
KH 39	S. flexneri	2009	0.75	16	12	mphA	-	+	
20094	S. sonnei	2010	1.42	32	9	ermB	+	+	
20343	S. sonnei	2010	1.58	512	6	mphA	+	+	
30295	S. sonnei	2010	1.75	512	6	mphA	+	+	

531 **Table 3.** Discrepancy rates of false-susceptible and false-resistant isolates detected using

			Discrepano	cies N(%)
Organism (breakpoint, g/L)	MIC range	Number	Very major	Major
S. flexneri (≤8)	$\geq R + 1$	3	0	NA
	$\mathbf{R} + \mathbf{S}$	4	0	1 (25)
	$\leq S + 1$	191	NA	5 (2.6)
	Total	198	0	6 (3.0)
S. sonnei (≤16)	$\geq R + 1$	14	0	NA
	$\mathbf{R} + \mathbf{S}$	2	0	0
	$\leq S + 1$	292	NA	3 (1.0)
	Total	308	0	3 (1.0)

Downloaded from http://aac.asm.org/ on February 8, 2018 by PERIODICALS OFFICE, MAIN LIBRARY, UNIVERSITY OF SHEFFIELD

532 proposed breakpoint criteria using an error rate-bounding method

534 R, non-susceptible MIC; S, susceptible MIC; NA, not applicable

535

536

537

Asia

AAC

Antimicrobial Agents and Chemotherapy

538	studies performed in Southeast Asia between 1994 and 2012 exhibiting different MICs
539	against azithromycin (mg/L).
540	
541	Figure 2. The relationship between azithromycin MIC and inhibition zone size in Southeast
542	Asian Shigella spp.
543	Plots showing the relationship between inhibition zone size (mm, x-axis) and MIC (mg/L, y-
544	axis) for azithromycin in S. flexneri (blue, left) and S. sonnei (green, right). The squares are
545	colored with respect to the number of isolates in each group, the number of isolate in each
546	group is additionally provided.
547	
548	Figure 3. Phylogenetic tree of S. sonnei in Southeast Asia
549	Phylogenetic tree of 261 S. sonnei genomes (global lineage III) and an additional 54 genomes
550	of isolates collected during the same period (1995-2011). Tree constructed through 2,812
551	chromosomal SNPs. Phylogenetic reconstruction was performed using multiple alignments of
552	SNPs by maximum-likelihood based phylogenetic inference and displayed and annotated
553	using iTOL. The year/period of isolation is highlighted in the outer ring and the organisms
554	with reduced susceptibility against azithromycin; mphA positive isolates are highlighted in red
555	and <i>ermB</i> positive isolates are highlighted in blue.
556	
557	Figure 4. Maps of azithromycin S. sonnei azithromycin resistant plasmids pDE105 and
558	pEG403_2
559	Maps of A) pDE105 and B) pEG403_2 azithromycin resistance plasmids isolated from
560	Vietnamese S. sonnei. The coding sequences of are number consecutively and notable
561	genes/regions are highlighted, which include DNA transfer regions, replication, antimicrobial

Figure 1. The distribution of azithromycin MICs for S. flexneri and S. sonnei in Southeast


Histograms showing the number of S. sonnei (green) and S. flexneri (blue) collected in 7

- resistance, and the azithromycin resistance genes (*ermB* and *mphA*, respectively). The size
- 563 (bp) of each plasmid are shown in the center.

564

Antimicrobial Agents and Chemotherapy





Downloaded from http://aac.asm.org/ on February 8, 2018 by PERIODICALS OFFICE, MAIN LIBRARY, UNIVERSITY OF SHEFFIELD

			Free	quen	cy S.	flexi	ıeri		0		1		5		10		30						Free	quen	cy S.	soni	nei
	6	9	10	11	12 A	13 zithr	14 omy	15 cin ii	16 nhibi	17 tion	18 zone	19 dia	20 mete	21 r (m	22 n)	23	25	26	27			6	9	10	11	12 A	13 zithr
0.5 -	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1		0.5 -	0	0	0	0	0	0
1 -	0	0	0	0	0	0	0	0	0	0	0	4	5	2	2	2	1	2	0		1 -	0	0	0	0	0	0
2 -	0	0	0	0	0	0	0	0	1	16	27	30	24	9	12	9	1	0	0		2 -	0	0	0	0	0	1
4 -	0	0	0	0	0	0	3	2	3	5	4	5	4	0	0	0	0	0	0	Azi	4 -	0	0	1	1	8	
8 -	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	thron	8 -	0	0	0	1	9	21
16 -	0	0	0	0	2	0	1	0	0	0	0	0	0	0	0	0	0	0	0	Azithromycin MIC	16 -	0	0	0	0	0	0
32 -	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		32 -	0	2	0	0	0	0
96 -	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	g/L	96 -	1	0	0	0	0	0
192 -	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		192 -	1	0	0	0	0	0
256 -	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		256 -	1	0	0	0	0	0
512 -	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		512 -	11	0	0	0	0	0

		Free	quen	cy S.	soni	nei		0		1		5		10		30		60	
	6	9	10	11	12 A	13 zithr	14 omy	15 cin ii	16 nhibi	17 tion	18 zone	19 diar	20 nete	21 r (m	22 n)	23	25	26	27
0.5 -	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
1 -	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
2 -	0	0	0	0	0	1	0	0	1	0	1	2	0	0	0	0	0	0	0
4 -	0	0	1	1	8		54		17	3	1	0	0	0	0	0	0	0	0
8 -	0	0	0	1	9	21			13	2	0	0	0	0	0	0	0	0	0
32 - 16 - 8 -	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
	0	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
96 -	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
192 -	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
256 -	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
512 -	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

